Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Release of 6-nitrodopamine from human popliteal artery and vein.
de Oliveira LFG, Britto-Júnior J, Lima AT, Moraes MO, Moraes MEA, de Souza VB, Schenka AA, Zakia Monica F, De Nucci G. de Oliveira LFG, et al. Life Sci. 2023 Aug 1;326:121801. doi: 10.1016/j.lfs.2023.121801. Epub 2023 May 25. Life Sci. 2023. PMID: 37244364
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.
Rocco PRM, Silva PL, Cruz FF, Melo-Junior MAC, Tierno PFGMM, Moura MA, De Oliveira LFG, Lima CC, Dos Santos EA, Junior WF, Fernandes APSM, Franchini KG, Magri E, de Moraes NF, Gonçalves JMJ, Carbonieri MN, Dos Santos IS, Paes NF, Maciel PVM, Rocha RP, de Carvalho AF, Alves PA, Proença-Módena JL, Cordeiro AT, Trivella DBB, Marques RE, Luiz RR, Pelosi P, Lapa E Silva JR; SARITA-2 investigators. Rocco PRM, et al. Among authors: de oliveira lfg. Eur Respir J. 2021 Jul 8;58(1):2003725. doi: 10.1183/13993003.03725-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33361100 Free PMC article. Clinical Trial.
Corrigendum to "Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban" [Vascular Pharmacology 124 (2020)/106608].
Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti Hayakawa GG, Montalvão S, Annichino-Bizzacchi JM. Ferreira T, et al. Among authors: de oliveira lfg. Vascul Pharmacol. 2020 Oct-Nov;133-134:106780. doi: 10.1016/j.vph.2020.106780. Epub 2020 Aug 28. Vascul Pharmacol. 2020. PMID: 32868216 No abstract available.
Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti-Hayakawa GG, Montalvão S, Annichino-Bizzacchi JM. Ferreira T, et al. Among authors: de oliveira lfg. Vascul Pharmacol. 2020 Jan;124:106608. doi: 10.1016/j.vph.2019.106608. Epub 2019 Oct 31. Vascul Pharmacol. 2020. PMID: 31678199
Epoxy-α-lapachone has in vitro and in vivo anti-leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite.
Souza-Silva F, Bourguignon SC, Pereira BA, Côrtes LM, de Oliveira LF, Henriques-Pons A, Finkelstein LC, Ferreira VF, Carneiro PF, de Pinho RT, Caffarena ER, Alves CR. Souza-Silva F, et al. Antimicrob Agents Chemother. 2015 Apr;59(4):1910-8. doi: 10.1128/AAC.04742-14. Epub 2015 Jan 12. Antimicrob Agents Chemother. 2015. PMID: 25583728 Free PMC article.